137 related articles for article (PubMed ID: 16171052)
1. [Type 2 diabetic as cardiovascular risk patient].
Krankenpfl J; 2005; 43(4-6):106. PubMed ID: 16171052
[No Abstract] [Full Text] [Related]
2. Implications of thiazolidinedione use and cardiovascular risk: is it all about the sugar?
Krantz MJ
Pharmacotherapy; 2006 Jul; 26(7):1049; discussion 1049-50. PubMed ID: 16803430
[No Abstract] [Full Text] [Related]
3. Implications of rosiglitazone and pioglitazone on cardiovascular risk in patients with type 2 diabetes mellitus.
Irons BK; Greene RS; Mazzolini TA; Edwards KL; Sleeper RB
Pharmacotherapy; 2006 Feb; 26(2):168-81. PubMed ID: 16466323
[TBL] [Abstract][Full Text] [Related]
4. [How does the PROactive Study change therapy of diabetes?].
Erdmann E
MMW Fortschr Med; 2005 Oct; 147(41):6. PubMed ID: 16270501
[No Abstract] [Full Text] [Related]
5. [Anti-diabetic treatment, insulin resistance and cardiovascular disease in patients with type 2 diabetes].
Hemmingsen B; Lund SS; Vaag A
Ugeskr Laeger; 2009 May; 171(19):1598-602. PubMed ID: 19419642
[TBL] [Abstract][Full Text] [Related]
6. [Glitazones critically evaluated].
Schernthaner G
Dtsch Med Wochenschr; 2007 Dec; 132(49):2619. PubMed ID: 18050024
[No Abstract] [Full Text] [Related]
7. [Pioglitazone protects the type-2-diabetes patient from myocardial infarction and stroke].
MMW Fortschr Med; 2007 Aug; 149(31-32):52-3. PubMed ID: 17849787
[No Abstract] [Full Text] [Related]
8. [Too positive comment on glitazones].
Lindberg M
Ugeskr Laeger; 2007 Feb; 169(8):733; author reply 733. PubMed ID: 17338040
[No Abstract] [Full Text] [Related]
9. Rationale for the use of insulin sensitizers to prevent cardiovascular events in type 2 diabetes mellitus.
Fonseca VA
Am J Med; 2007 Sep; 120(9 Suppl 2):S18-25. PubMed ID: 17826042
[TBL] [Abstract][Full Text] [Related]
10. Effect of pioglitazone on the drivers of cardiovascular risk in type 2 diabetes.
Donnelly R
Int J Clin Pract; 2007 Jul; 61(7):1160-9. PubMed ID: 17511791
[TBL] [Abstract][Full Text] [Related]
11. [Glitazone - mailing no 1. In response to DMW 49/2007].
Traut V
Dtsch Med Wochenschr; 2008 Feb; 133(6):261; author reply 262-3. PubMed ID: 18236356
[No Abstract] [Full Text] [Related]
12. [Insulin resistance increases risk of infarct. Glitazone now approved also for monotherapy].
MMW Fortschr Med; 2003 Sep; 145(38):61. PubMed ID: 14603688
[No Abstract] [Full Text] [Related]
13. [World news in age-related diabetes: blood sugar lowering can improve prognosis].
Einecke D
MMW Fortschr Med; 2005 Sep; 147(38):1. PubMed ID: 16218218
[No Abstract] [Full Text] [Related]
14. PROactive Study: (r)evolution in the therapy of diabetes?
Ceriello A
Diabet Med; 2005 Nov; 22(11):1463-4. PubMed ID: 16241907
[No Abstract] [Full Text] [Related]
15. [The PPARgamma receptor agonists and prevention of cardio-vascular complications in patients with type 2 diabetes. The results of the PROactive study].
Szymborska-Kajanek A; Strojek K
Kardiol Pol; 2006 Mar; 64(3):322-5; discussion 325-6. PubMed ID: 16583340
[No Abstract] [Full Text] [Related]
16. [Glitazone - mailing no 3. In response to DMW 49/2007].
Gundel UF
Dtsch Med Wochenschr; 2008 Feb; 133(6):261-2; author reply 262-3. PubMed ID: 18236354
[No Abstract] [Full Text] [Related]
17. [Trial of pioglitazone for the secondary prevention of cardiovascular events in patients with diabetes mellitus type 2: insufficient evidence].
Veneman TF
Ned Tijdschr Geneeskd; 2006 Apr; 150(16):931-2; author reply 932-3. PubMed ID: 16686096
[No Abstract] [Full Text] [Related]
18. [Trial of pioglitazone for the secondary prevention of cardiovascular events in patients with diabetes mellitus type 2: insufficient evidence].
Heine RJ
Ned Tijdschr Geneeskd; 2006 Apr; 150(16):930-1; author reply 932-3. PubMed ID: 16686095
[No Abstract] [Full Text] [Related]
19. Pleiotropic effects of thiazolidinediones.
Rizos CV; Liberopoulos EN; Mikhailidis DP; Elisaf MS
Expert Opin Pharmacother; 2008 May; 9(7):1087-108. PubMed ID: 18422468
[TBL] [Abstract][Full Text] [Related]
20. Optimizing antidiabetic treatment options for patients with type 2 diabetes mellitus and cardiovascular comorbidities.
Malesker MA
Pharmacotherapy; 2008 Feb; 28(2):193-206. PubMed ID: 18225965
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]